Prof. Dr. Andreas Hochhaus

Andreas Hochhaus

Image: Andreas Hochhaus

Department of Internal Medicine II
Department of Hematology and Internal Oncology
University Hospital Jena
Am Klinikum 1, 07747 Jena
Phone: +49 3641 9 324 201
Fax:      +49 3641 9 324 202
andreas.hochhaus@med.uni-jena.de
HomepageExternal link

Functions

  • Director of the Department of Hematology and Internal Oncology of KIM II
  • Speaker of the University Tumor Center
  • Vice Dean for Research

Research

  • Chronic myeloid leukemia
  • Chronic myeloproliferative disorders
  • Minimal residual disease
  • signaling

Publications (selected 5 most recent)

  1. Saussele S, Richter J, Guilhot J, ..., Hochhaus A, Pfirrmann M, Mahon FX: "Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial" Lancet Oncol. 2018 Jun;19(6):747-757
  2. Xiao G, ... Ernst T, Hochhaus A, ..., Müschen M. "B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies" Cell. 2018 Apr 5;173(2):470-484.e18. doi: 10.1016/j.cell.2018.02.048.
  3. Mathew NR, ..., Hilgendorf I, Hochhaus A, .... Zeiser R. "Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells" Nat Med. 2018 Mar;24(3):282-291.
  4. Hochhaus A, Larson RA, Guilhot F, et al. "Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia" N Engl J Med. 2017 Mar 9;376(10):917-927.
  5. Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T. "Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms" Leukemia. 2017 Sep;31(9):1936-1943.